Drugs /

rintatolimod

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Atvogen acts through a number of pathways to stimulate intracellular antiviral activity of the immune system: it stimulates interferon production; activates the oligoadenylate synthase-RNase L pathway; stimulates natural killer cell activity; and acts as a non-mitogenic stimulator of the immune system. This agent also inhibits replication of human immunodeficiency virus (HIV) in vitro. (NCI04)

Clinical Trials

View Clinical Trials for rintatolimod

Rintatolimod has been investigated in 9 clinical trials, of which 8 are open and 1 is closed. Of the trials investigating rintatolimod, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 5 are phase 2 (5 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for rintatolimod clinical trials.

Breast carcinoma, fallopian tube adenocarcinoma, and fallopian tube carcinosarcoma are the most common diseases being investigated in rintatolimod clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rintatolimod
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rintatolimod
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rintatolimod and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
atvogen, (ri(n).r(c(12)u)n), ampligen, rintatolimod, poly(i):poly(c12u) rna, poly(i)-poly(c12u), poly(inosinic acid) poly(cytidylic(12), uridylic)acid, poly(inosinic acid) poly(cytidylic(12), uridylic)acid, poly(i).poly(c12,u), atvogen, poly(i).poly(c12,u), ampligen
Drug Target(s) [2]:
TLR3
NCIT ID [1]:
C1001

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.